Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.

Zhang, Steven; Jin, Shu; Griffin, Celina; Feng, Zhongling; Lin, Jianchang; Baratta, Mike; Brake, Rachael; Venkatakrishnan, Karthik; Gupta, Neeraj

Zhang, Steven; Jin, Shu; Griffin, Celina; Feng, Zhongling; Lin, Jianchang; Baratta, Mike; Brake, Rachael; Venkatakrishnan, Karthik; Gupta, Neeraj.

Afiliação

Zhang S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Jin S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Griffin C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Feng Z; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Lin J; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Baratta M; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Brake R; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Venkatakrishnan K; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Gupta N; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Clin Pharmacol Drug Dev ; 10(9): 1028-1043, 2021 09.

Article em En | MEDLINE | ID: mdl-34118178

Assuntos

Compostos de Anilina/administração & dosagem; Interações Alimento-Droga; Indóis/administração & dosagem; Inibidores de Proteínas Quinases/administração & dosagem; Pirimidinas/administração & dosagem; Administração Oral; Adolescente; Adulto; Compostos de Anilina/efeitos adversos; Compostos de Anilina/farmacocinética; Disponibilidade Biológica; Estudos de Coortes; Estudos Cross-Over; Relação Dose-Resposta a Droga; Método Duplo-Cego; Feminino; Meia-Vida; Humanos; Indóis/efeitos adversos; Indóis/farmacocinética; Masculino; Pessoa de Meia-Idade; Inibidores de Proteínas Quinases/efeitos adversos; Inibidores de Proteínas Quinases/farmacocinética; Pirimidinas/efeitos adversos; Pirimidinas/farmacocinética; Equivalência Terapêutica; Adulto Jovem

Palavras-chave

EGFR exon 20; food effect; non-small cell lung cancer; safety; tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Interações Alimento-Droga / Inibidores de Proteínas Quinases / Indóis / Compostos de Anilina Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google